What's Going on With ARS Pharma Stock Thursday? - ARS Pharmaceuticals (NASDAQ:SPRY)
ARS Pharmaceuticals (NASDAQ:SPRY) announced a leadership change. Co-founder and CEO Richard Lowenthal stepped down as employee and officer effective July 6, 2026. Donn Casale, president, was appointed CEO and director effective July 7, 2026. William Blair and analyst Lachlan Hanbury-Brown discussed a more cautious neffy outlook, lowering Q2 neffy revenue to $26.4M and fair value to $21 from $31; SPRY was down 1.6% to $7.97.
How this was made
The 30-second read
Why it matters
The combination of management change and analyst estimate reductions (peak penetration, prescriptions, Q2 revenue, and fair value) raises the probability of further expectation resets around Neffy demand and strategy.
Market read
Traders may reprice SPRY around Neffy demand expectations and management execution risk ahead of the Q2 earnings call.
What to watch
The article cites inventory build offsetting lower prescriptions, so near-term revenue may be less weak than prescriptions alone suggest; the Q2 call could also change the adoption narrative.
Background
ARS Pharma is navigating a Neffy launch that analysts say has not met earlier expectations, and it has now executed a CEO transition effective July 7, 2026.
Ticker impact
ARS Pharmaceuticals announced CEO/co-founder Richard Lowenthal stepping down and Donn Casale becoming CEO, plus William Blair cut estimates for Neffy.
Bias to downside or higher volatility until the Q2 earnings call clarifies Neffy strategy and demand trajectory.
The article pairs a fresh executive transition with specific analyst estimate cuts (revenue, fair value, penetration, prescriptions), which typically pressures sentiment and expectations ahead of the next earnings call.
Market effects
Could affect sentiment across vaccine commercialization stories, especially for companies tied to Neffy-like launch execution and adoption curves.
Primarily US small/mid-cap biotech sentiment, with limited direct regional spillover implied.
Limited global read-through; the catalyst is company-specific (Neffy commercialization and management transition).
Counterpoint
Casale’s appointment may be viewed as a commercialization-focused reset, and the “measured” base case could already be priced in if investors expected volatility around Neffy adoption.
Key entities
- public_companySPRY
ARS Pharmaceuticals, subject of the leadership transition and analyst estimate revisions tied to Neffy.
- executiveRichard Lowenthal
Co-founder and CEO who stepped down effective July 6, 2026.
- executiveDonn Casale
President appointed CEO and director effective July 7, 2026.
- analyst_firmWilliam Blair
Issued a note discussing the abruptness of the CEO move and later estimate changes for Neffy.
- analystLachlan Hanbury-Brown
Analyst who lowered Neffy penetration and revised Q2 revenue and fair value estimates.
